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Magnetic Resonance (MR) Patterns of Brain Metastasis in
Lung Cancer Patients
Correlation of Imaging Findings with Symptom
Amarnath Jena, DNB (NM),* Sangeeta Taneja, DNB (Radiodiagnosis),*
Vineet Talwar, MD, DM (Med Oncology),† and Jai Bhagwan Sharma, MD, DM (Med Oncology)†
Introduction: Asymptomatic brain metastasis in lung cancer pa-
tients, if detected early have been reported to show survival benefit
with treatment. These asymptomatic metastasis have been found to
be smaller and less in number than those with symptoms. We
however observed that many lung cancer patients bear a significant
metastatic load in the brain irrespective of the stage or neurologic
symptoms at the time of initial presentation.
Material and Methods: A retrospective study was conducted on
175 patients of proven non-small cell lung cancer to assess the
patterns of brain metastasis in the two groups of patients, with and
without neurologic symptoms. All patients had undergone screening
magnetic resonance imaging for brain metastasis as an initial staging
protocol. The patients with brain metastasis were divided into two
groups: asymptomatic (group I) and symptomatic (group II). The
lesions were studied with regards to the number, size, site, nature
(solid with and without necrosis), and presence of perilesional
edema and intralesional hemorrhage in both the groups in various
stages of disease.
Results: Brain metastasis was seen in 62 (31.3%) patients of whom
46.7% were neurologically asymptomatic. Patients (90.3%) with
brain metastasis were in stage IV at the time of presentation. No
statistically significant correlation was found between the two
groups regarding the number of lesions (p  0.554), size of lesion
(p  0.282), site of lesion (p 0.344), nature of lesion (p 0.280),
presence of perilesional edema (p 0.404), and presence or absence
of intralesional hemorrhage (p  0.09). In our study, brain metas-
tases were present only in stages III and IV disease with no
statistically significant difference in the lesion patterns.
Conclusion: The study reveals almost equal number of patients with
brain metastasis in the symptomatic and asymptomatic groups with
no significant difference in lesion patterns. We therefore conclude
that although imaging surveillance of the brain for metastasis will
detect asymptomatic metastasis early for early institution of appro-
priate therapy the prognosis in these patients would not solely
depend on the presence or absence of symptoms and the pattern of
lesion may have an influence on the patients’ response to therapy
and survival benefit specially for those asymptomatic patients with
equally large metastatic load.
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Brain is one of the common sites of distant metastasis aswell as initial recurrence in patients of lung cancer with
an incidence of 20% at diagnosis and upto more than 50% at
autopsy.1–3 Non-small cell lung cancer (NSCLC) does not
have a set of clinical pattern of metastasis and brain metas-
tasis may exist in neurologically asymptomatic patients. Sev-
eral studies have documented the incidence of asymptomatic
brain metastasis and have stressed upon the importance of
screening magnetic resonance (MR) imaging of brain in patients
with lung cancer to detect occult brain metastasis so as to
provide survival benefit by allowing earlier treatment of brain.
Demange et al.4 reported better survival for patients in
good neurologic condition at the time metastasis was discov-
ered in patients with resectable NSCLC. Kim et al.,5 in their
study, observed that patients with less number of lesions
survived better. In a follow-up study of brain with computed
tomography (CT) in patients with resected lung cancer, Kohei
Yokoi et al.6 reported that asymptomatic metastasis were
small in number and size (measuring less than 2.5 cm).
In our clinical setting, however, we observed patients of
NSCLC with large metastatic load in brain at the time of
initial presentation, were neurologically asymptomatic. This
prompted us to study whether imaging pattern of brain
metastasis is in any way different in the symptomatic and
asymptomatic patients.
MATERIALS AND METHODS
This study was approved by our Institutional Review
Board. Database search of the cases attending a medical
oncology clinic of our institute identified 175 patients of
proven NSCLC (age group 32–80 years, male-to-female ratio
152:23) who were treated between 2003 and 2006. Only
those patients who underwent MR imaging of the brain as
part of initial staging work up, besides the routine clinical,
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hematological examinations and other staging procedures
(including CT scan of the chest and upper abdomen, Tc 99m
Methylene Di-phosphonate bone scan) were included in the
study. These patients’ records including radiology, pathol-
ogy, clinical notes, and discharge summaries were reviewed
by the medical oncologist for presence/absence of neurologic
symptoms. The medical oncologist was blinded as regards the
presence or absence of brain metastasis on MR imaging,
while reviewing the files. The staging was done by the
medical oncologist according to the international system for
T, N, and M staging of lung cancer without considering the
findings on MR brain. MR imaging of brain was done on 1.0
T MR System (MAGNETOM EXPERT, Siemens, Germany)
in all the cases. Imaging protocol included Fluid attenuation
inversion recovery, and T1 Spin echo sequences (with Mag-
netization transfer suppression) in axial and coronal planes.
Postcontrast T1 SE images were obtained after administration
of 0.1 mmol/kg body weight of gadobenate dimeglumine. An
additional axial Gradient-recalled echo sequence to detect
magnetic susceptibility effect was taken to rule out any old
hemorrhage in the lesion. In all cases, slice thickness was 5
mm with 10% interslice gap and matrix size of 256  256.
The MR imaging were analyzed by two different radi-
ologists independently, unaware of the patients neurologic
status and stage of disease, for the number and size of the
lesion, the site of lesion (supratentorial [ST]/infratentorial
[IT]), nature (solid with and without necrosis), presence of
perilesional edema, intralesional hemorrhage, and finding
taken in consensus was included for analysis. Interobserver
agreement was excellent with [kappa] coefficient of 0.89 for
MR findings.
Patients, who had brain metastasis shown by MR im-
aging at initial staging, were divided into two groups; group
I included neurologically asymptomatic patients and group II
included patients who had neurologic symptoms. The neuro-
logic symptoms which were considered were headache, sei-
zures, sensory or motor deficit. Patients with osseous metas-
tasis having neurologic deficit because of extradural cord
compression were not included in the study. The largest
dimension in any plane on postcontrast axial or coronal
images was taken into consideration. The nonenhancing area
of altered signal intensity beyond the enhancing component
was considered as perilesional edema.
p Value was calculated for these parameters using the
Pearson’s 2 test (using SPSS (Department of Biostatistics,
AJIMS, New Delhi, India) version 10) to assess the level of
significance of presence of these features with patients’
symptom.
RESULTS
Demographic information of the two study groups is
listed in Table 1. Of the 175 patients, 62 (35.4%) patients had
brain metastasis of which 29 (46.7%) patients were neuro-
logically asymptomatic (group 1). Thirty-three (53.2%) pa-
tients with brain metastasis had neurologic symptoms (group
2) at the time of initial presentation. The probability of
finding symptomatic and asymptomatic metastasis in patients
with lung cancer is almost same.
The stage-wise distribution of patients in the asymp-
tomatic and symptomatic groups is depicted in Table 2.
Patients (68.5%)were in stage IV at presentation. Of our 62
patients 56 (90.3%) with brain metastasis were already in
stage IV, of which, 44.6% were asymptomatic at presenta-
tion. Six patients had stage III disease, of which, four were
asymptomatic. None of our stage I and II patients (n  17)
had brain metastasis.
Table 3 shows the distribution of neurologic symptoms
in patients with brain metastasis. Most common symptom
encountered was seizure,7 followed by headache.8
Table 4 shows the distribution of the lesion patterns on
MR imaging among the symptomatic and asymptomatic
groups.
Eighteen patients had a solitary focus of metastasis of
which 11 (61%) were symptomatic. Although four patients in
each group (groups I and II) had considerable lesion load in
brain with more than 10 lesions, 75.8% of asymptomatic
TABLE 1. Demographic Distribution of Patients with Lung
Cancer
Total Asymptomatic Symptomatic
Age range (yr) 32–80 32–78 34–75
Mean age (yr) 60 59 56
Male 152 23 28
Female 23 6 5
TABLE 2. Stage Wise Distribution of Patients with NSCLC*
Stage
Total Patients
(n  175)
BM (n  62)
No BM
Asymptomatic,
Group I
(n  29)
Symptomatic,
Group II
(n  33)
I 2 0 0 2
IIa 5 0 0 5
IIb 10 0 0 10
IIIa 15 0 1 14
IIIb 23 4 1 18
IV 120 25 31 64
*Staging of the patients has been done according to the international system of
staging lung cancer without considering the MR brain findings.
NSCLC, non-small cell lung cancer; BM, brain metastasis.
TABLE 3. Distribution of Symptoms with and without Brain
Metastasis
Symptom Metastatic (33) Nonmetastatic (7)
Headache 4 1
Vomiting 4 3
Headache and vomiting 7 0
Neurological deficit 7 0
Seizures 8 1
Visual 3 1
Sensorium 5 1
Ataxia 1 0
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patients had multiple brain metastases (Figures 1 and 2).
There was no statistically significant difference in the number
of lesions in the two groups (p  0.410). Although, of the 15
patients with lesion size 1 cm, six patients (40%) were
neurologically symptomatic, seven patients (35%) with lesion
size 2.5 cm were found asymptomatic. Twenty-seven of 62
(43.5%) patients had maximum lesion size varying from 1 to
2.5 cm. Mean lesion size was 2.2 cm in symptomatic group
and 1.8 cm in the asymptomatic group. The largest lesion size
in asymptomatic group was 5.4 cm (Figure 3). There was no
significant difference in the size of lesion in symptomatic and
asymptomatic groups (p value  0.282).
Patients (36.8%) having lesions associated with hem-
orrhage were without any symptoms (Figure 4). Fifty-three of
the 62 patients who had associated perilesional edema, 43.4%
patients were asymptomatic (Figure 3). Although, 30 of 53
(56.6%) patients with edema related to brain metastasis were
clinically symptomatic, 23 of 29 (79%) asymptomatic pa-
tients had associated perilesional edema. There was no sig-
nificant difference in the number of patients in both the
groups as regards the presence or absence of perilesional
edema (p value  0.404) and hemorrhage within the lesions
(p  0.1).
Fifty percentage of the solid lesions were asymptom-
atic. Lesions with necrosis were present in 16 patients of
which six (37.5%) were without neurologic symptoms with
no statistically significant difference (p  0.280).
Lesions were present in both ST and IT compartments
in 25 patients of which 56% (14 of 25) were asymptomatic.
Thirty-four patients had lesions confined to the ST compart-
ment of which 44.1% (15 of 34) patients were asymptomatic.
All the three patients having lesions confined to IT compart-
ment in this study were found symptomatic. The number of
patients with lesions in the IT compartment is too less for any
statistical calculation.
Table 5 shows the stage-wise distribution of lesion pat-
terns. In our study, none of the patients in stages I and II had
brain metastasis. We found no significant difference in the lesion
pattern in patients with stage III and stage IV disease.
FIGURE 1. A, Axial FLAIR. B, Axial postcon-
trast T1W. C, Coronal postcontrast T1W. A 62-
year-old neurologically asymptomatic man
with NSCLC of the left lung with multiple me-
tastasis in both supra and infratentorial com-
partments and associated perilesional edema.
FIGURE 2. A, Axial FLAIR. B and C, Postcon-
trast T1W. A 48-year-old neurologically asymp-
tomatic man with adenocarcinoma of the right
lung—stage IV disease with osseous, hepatic,
and pulmonary metastasis and multiple lesions
in both supra and infratentorial compartments
of brain.
TABLE 4. Distribution of Lesion Pattern in Both Groups
Asymptomatic
(29)
Symptomatic
(33) p
No. of lesions 0.410
Solitary 7 11
Multiple 22 22
10 4 4
Size of lesions 0.282
1 9 6
1–2.5 13 14
2.5 7 13
Mean lesion size (cm) 1.8 2.2
Maximum size (cm) 5.4 5.0
Oedema 0.404
 23 30
 6 3
Hemorrhage 0.1
 7 12
 22 21
Solid with and without necrosis 0.280
Solid without necrosis 23 23
Solid with necrosis 6 10
Site 0.344
ST 15 19
BO 14 11
IT 0 3
ST, supratentorial; BO, both; IT, infratentorial; , present; , absent.
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DISCUSSION
Approximately 25 to 30% of patients with lung cancer
develop brain metastasis at some stage and the incidence at
the initial work up has been reported to be between 12% and
18%.5,7,8 Hochstenbag et al.9 in 2003, and Kim et al.5 in 2005,
have documented incidence of brain metastasis in patients
with lung cancer to be 14% and 18.9%, respectively. In our
study, 35.4% patients with newly diagnosed lung cancer had
brain metastasis on MR imaging at the time of initial staging.
This is probably because we had a large number of patients
(68.5%) in stage IV. Although none of our patients with
stages I and II had brain metastasis, only 6 of 38 patients with
stage III disease had brain metastasis. It corroborates with the
fact that the incidence of brain metastasis increases with
advancing stage of the disease.5,9
The prognosis for patients with brain metastasis who go
untreated is extremely poor (about 1 month after diagnosis),2
whereas patients with NSCLC who are treated with radiation
therapy survive for about 8 months.10 Improvements in sys-
temic and local therapies can improve the long-term survival
of cancer patients, which means that early and accurate
diagnosis of BM has become crucial to improving quality of
life and poor survival rates of cancer patients.
In our study, asymptomatic brain metastasis was found
in about 16.5% of lung cancer patients which was in agree-
ment with previous studies.5,9 Patients (44.6% of stage IV)
and 66.6% of stage III patients with brain metastasis were
asymptomatic at presentation. However, we did not find any
statistically significant difference between symptom and
stage of disease (p  0.308). This is in concordance with the
findings of Shi et al.11 stating that the patient symptom is
independent of the stage of disease at presentation.
The prognosis of patients with symptomatic brain me-
tastasis is substantially worse than those in which metastasis
are asymptomatic.4 Several reports in the past have empha-
sized screening of the brain for early detection of brain
FIGURE 3. Axial (A) FLAIR, (B) FLASH 2d, (C)
postcontrast T1W. A 64-year-old neurologically
asymptomatic man with stage IV NSCLC of
the left lung with solitary hemorrhagic and ne-
crotic metastasis in the right parietal lobe mea-
suring 4.4 cm.
FIGURE 4. Axial (A) FLAIR, (B) FLASH 2d, (C)
Coronal postcontrast T1W. A 71-year-old neu-
rologically asymptomatic man with adenocarci-
noma of the left lung in stage IV with multiple
hemorrhagic metastases largest in the right
temporo-occipital region measuring 3.9 cm.
TABLE 5. Stage Wise Distribution of Lesion Patterns in Both
Groups
Stage of Disease I II (6) III IV (56) p
No. of lesions 1.0
Solitary 0 0 2 16
Multiple 0 0 4 40
10 0 0 1 8
Size of lesions 0.61
1 0 0 2 11
1–2.5 0 0 3 26
2.5 0 0 1 19
Mean lesion size (cm) 0 0 1.7 2.1
Maximum size (cm) 0 0 4.5 5.4
Oedema 0.25
 0 0 4 48
 0 0 2 8
Hemorrhage 0.66
 0 0 1 18
 0 0 5 38
Solid with and without necrosis 1.0
Solid without necrosis 0 0 5 40
Solid with necrosis 0 0 1 16
Site 0.75
ST 0 0 4 30
BO 0 0 2 23
IT 0 0 0 3
ST, supratentorial; BO, both; IT, infratentorial; , present; , absent.
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metastasis with survival benefit in those who are in good
neurologic condition at presentation. Kim et al.5 in 2005,
reported better survival in patients who had less than three
metastatic foci with a statistically significant difference in the
median survival in patients with 1 to 3 and3 foci. However,
their study does not mention the distribution of these meta-
static foci in symptomatic and asymptomatic groups.
In our study, we found no statistically significant dif-
ference (p  0.554) in the number of lesions in both groups
of patients. Equal numbers of symptomatic and asymptomatic
patients were found to harbor a sizeable metastatic load.
Asymptomatic patients with a large metastatic load may not
have survival benefit over those symptomatic patients with a
smaller load. Kim et al.,5 also reported that there was no
statistically significant difference in the survival rate in symp-
tomatic and asymptomatic patients. They, however, reasoned
it probably to be because of early and aggressive treatment in
both groups of patients with and without symptoms.
In a follow-up study of brain with CT in patients with
resected lung cancer, Kohei Yokoi et al.6 found asymptomatic
metastasis in 63.6% of their cases and reported that the
number of metastasis in all asymptomatic patients was small
and maximum size of almost all lesions were less than 25
mm. We have found no statistically significant association
between presence of symptom and size of the lesion (p 
0.282) with an overlap in lesion size between the two groups
of patients. The disparity could be because of the modality
used (CT instead of MR imaging) and limited number of
patients in their study (n  11). Moreover, the largest lesion
in their study (lesion size 3.7 cm) was not associated with any
symptoms and equal number of patients with and without
symptoms (n  2) harbored lesions measuring 2.5 cm. Also,
no overall correlation was found between the site of lesion
and symptoms (p  0.344) though all three IT lesions were
symptomatic in our study. Shi et al., also found similar
observation as regards the number and distribution of brain
metastasis.10
We did not find any reported studies that mention
influence of other contributory factors (viz presence of
edema, hemorrhage, and necrosis within the lesions) on
patients’ symptoms at presentation. We found no association
between presence of perilesional edema and symptoms (p 
0.027) and 41.8% of patients with perilesional edema were
silent at presentation. Although 63.1% of patients with in-
tralesional hemorrhage were symptomatic at presentation,
24.1% of asymptomatic patients had associated hemorrhage
(p  0.09). We also did not find any statistically significant
difference in the two groups as regards to nature of lesions
with and without necrosis.
CONCLUSION
The incidence of asymptomatic brain metastasis in our
study was 16.5% with almost equal number of symptomatic
and asymptomatic metastasis in lung cancer patients. Hence,
imaging surveillance of the brain for metastasis is worthwhile
to detect asymptomatic metastasis early for early institution
of appropriate therapy. In our study, we have found no
significant difference between the neurologically symptom-
atic and asymptomatic patients as regards the various lesion
parameters (viz., size, number, site, presence or absence of
edema, hemorrhage, and necrosis) and asymptomatic patients
had an equally large metastatic load. These asymptomatic
patients may not have survival benefit over those symptom-
atic patients with a smaller load. Hence, we would like to
state that the prognosis in patients with brain metastasis
would not solely depend on the presence or absence of
symptoms as has been described previously in literature and
the pattern of lesion may have an influence on the patients’
response to therapy and hence the survival benefit. Because
our study lacks survival data because of poor follow-up of
patients, further work is needed to study the influence of
lesion pattern on the patients’ response to therapy and assess
the exact survival benefit.
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